MedTrace Logo

Mesenchymal Stem Cells in Patients Diagnosed With COVID-19

NCT04611256 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-11-12

No results posted yet for this study

Summary

The propose of this study is implement adjuvant therapy with adipose tissue derived-mesenchymal stem cells (MSCs) for critical COVID-19 patients admitted to the intensive care unit of the Regional Hospital Lic. Adolfo López Mateos of the Institute for Social Security and Services for State Workers to reduce cytokine storm and contribute to the favorable resolution of respiratory insufficiency and multiple organic failure.

Conditions

  • Covid19

Interventions

BIOLOGICAL

MSC

Two intravenous infusion of 1\*10E6 adipose tissue derived-MSCs /kg body weight reach

DRUG

Control

Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.

Sponsors & Collaborators

  • Instituto de Terapia Celular: ITC

    collaborator UNKNOWN

  • Hospital Reg. Lic. Adolfo Lopez Mateos

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2020-11-30
Completion
2020-12-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04611256 on ClinicalTrials.gov